We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 24, 2014

Benefit From Alkylating-Agent Chemotherapy in Oligodendrogliomas Associated With IDH Mutation

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of IDH
J. Clin. Oncol 2014 Feb 10;[EPub Ahead of Print], JG Cairncross, M Wang, RB Jenkins, EG Shaw, C Giannini, DG Brachman, JC Buckner, KL Fink, L Souhami, NJ Laperriere, JT Huse, MP Mehta, WJ Curran

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading